Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2581502 | 0.98 | ALDH1A1 (0.40) | ALDH1A1LMNATSHRESR1CHRM1 | |
| SCHEMBL23581909 | 0.90 | ESR1 (0.48) | ALDH1A1LMNATSHRESR1CHRM1 | |
| SCHEMBL2585836 | 0.87 | TSHR (0.38) | LMNATSHRESR1CYP3A4KDM4E | |
| Hydrochloric Acid SCHEMBL2582658 | 0.86 | KMT2A (0.38) | LMNATSHRESR1CYP3A4KDM4E | |
| SCHEMBL9805766 | 0.78 | CHRM3 (0.46) | LMNATSHRCHRM1TDP1CHRM2 | |
| Iodide SCHEMBL28802571 | 0.77 | CHRM3 (0.45) | LMNATSHRCHRM1TDP1CHRM2 | |
| SCHEMBL3044281 | 0.77 | ESR1 (0.42) | ALDH1A1LMNATSHRESR1TDP1 | |
| SCHEMBL28408947 | 0.75 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRESR1CHRM1 | |
| SCHEMBL468058 | 0.72 | TSHR (0.37) | TSHRTDP1MAPK1 | |
| SCHEMBL28702490 | 0.72 | TSHR (0.37) | TSHRTDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108553-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | CORTRIA CORPORATION (US) | 2012-05-03 | — | — | US | claimed |
| US-20110269724-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | CORTRIA CORPORATION (US) | 2011-11-03 | — | — | US | claimed |
| EP-1147086-B9 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | PHARMENA SP Z O O (PL) | 2010-09-22 | — | — | EP | claimed |
| EP-2203055-A1 | 1-METHYL NICOTINAMIDE AND DERIVATIVES FOR TREATMENT OF GASTRIC INJURY | Cortria Corporation (US) | 2010-07-07 | — | — | EP | claimed |
| US-20090118225-A1 | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury | CORTRIA CORPORATION (US) | 2009-05-07 | — | — | US | claimed |
| WO-2009042440-A1 | 1-METHYL NICOTINAMIDE AND DERIVATIVES FOR TREATMENT OF GASTRIC INJURY | CORTRIA CORPORATION (US) | 2009-04-02 | — | — | WO | claimed |
| EP-2026651-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2009-02-25 | — | — | EP | claimed |
| EP-1919466-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2008-05-14 | — | — | EP | claimed |
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PHARMENA NORTH AMERICA INC. (CA) | 2007-11-08 | — | — | US | claimed |
| WO-2007103540-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2007-09-13 | — | — | WO | claimed |
| WO-2007074406-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2007-07-05 | — | — | WO | claimed |
| EP-1147086-B1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2005-03-30 | — | — | EP | claimed |
| EP-1147086-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | Technical University of Lodz (PL) | 2001-10-24 | — | — | EP | claimed |
| WO-2000040559-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2000-07-13 | — | — | WO | claimed |
| US-8481570-B2 | 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities | CORTRIA CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120245115-A1 | 1-Methylnicotinaide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities | CORTRIA CORPORATION (US) | 2012-09-27 | — | — | US | disclosed |
| US-8211922-B2 | 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | CORTRIA CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1147086-B1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2005-03-30 | — | — | EP | disclosed |
| EP-1147086-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | Technical University of Lodz (PL) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000040559-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PTGS1, PTGS2, PTGES2 | ALDH1A1 725/4885LMNA 2772/4885TSHR 3705/4885 |
| US-20110269724-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | PTGS1, PTGS2, PTGES2 | ALDH1A1 725/4885LMNA 2772/4885TSHR 3705/4885 |
| US-20090118225-A1 | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury | NNMT, NAMPT, NNT | ALDH1A1 521/4885LMNA 1590/4885TSHR 3773/4885 |
| US-20120108553-A1 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries | PTGS1, PTGS2, PTGES2 | ALDH1A1 725/4885LMNA 2772/4885TSHR 3705/4885 |
| US-20120245115-A1 | 1-Methylnicotinaide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities | HMGCR, NNMT, NAMPT | ALDH1A1 1312/4885LMNA 121/4885TSHR 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.